Stem Point Capital LP Portfolio Holdings

Stem Point Capital LP

  • $312 Billion
  • Q2 2025

Stem Point Capital LP has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $312 Billion distributed in 54 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Syndax Pharmaceuticals Inc with a value of $22.2B, Immunovant, Inc. with a value of $20.8B, Scholar Rock Holding Corp with a value of $18.7B, Centessa Pharmaceuticals PLC with a value of $16.6B, and Madrigal Pharmaceuticals, Inc. with a value of $15.9B.

Examining the 13F form we can see an decrease of $2.13B in the current position value, from $314B to 312B.

Stem Point Capital LP is based out at New York, NY

Below you can find more details about Stem Point Capital LP portfolio as well as his latest detailed transactions.

Portfolio value $312 Billion
Healthcare: $256 Billion

Stock Holdings Table Market Cap. of $50 Millions to $300 Millions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$241M
$2.88 Billion 0.92% of portfolio
644,654
Q2 2025 New
$141M
$2.78 Billion 0.89% of portfolio
1,203,941
Q2 2025 New
$228M
$759 Million 0.24% of portfolio
283,286
Q2 2025 New

Summary

  • Portfolio
  • No. of Stocks 54
  • Current Value $312 Billion
  • Prior Value $314 Billion
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 18 stocks
  • Additional Purchases 16 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 15 stocks
Track This Portfolio

Track Stem Point Capital LP Portfolio

Follow Stem Point Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stem Point Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Stem Point Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email